Answers are grounded in this paper and cite their sources.
Demonstrates lower disease activity and higher biologic use in adult juvenile idiopathic arthritis versus matched rheumatoid arthritis, indicating distinct clinical profiles.
Objective: To evaluate the difference between adult juvenile idiopathic arthritis (JIA, starting at <16 years) and rheumatoid arthritis (RA). Methods: Data on 128 adult JIA patients were from the National Database of Rheumatic Diseases in Japan (NinJa), 2014, divided into 4 groups by period of disease onset (Group 1: 2000–2013, n = 32; Group 2: 1981–1999, n = 32; Group 3: 1966–1980, n = 31; Group 4: ∼1965, n = 33). Disease activity, treatment and long-term prognosis of adult JIA patients were compared with RA patients matched for sex- and disease duration in each era. Results: In Groups 1 and 2, adult JIA patients had significantly lower clinical disease activity indices (CDAI) (Group 1: adult JIA 1.5 [0.4–6.9]-vs-RA 5.3 [2.5–10.3], p = .001, Group 2: 2.6 [0.6–9.0]-vs-6.9 [3.5–11.0], p = .001, shown as median [quartile range], p-value, respectively), and had higher CDAI remission rates than RA patients (Group 1: 54.8%-vs-28.2%, p = .002, Group 2: 51.7%-vs-17.0%, p < .001). More adult JIA than RA patients in Group 1 used biologics (62.5%-vs-24.7%, p < .001). However, there were no adult JIA-vs-RA differences in joint destruction and physical function in any group. Conclusions: Adult rheumatologists must recognize that adult JIA patients are different from RA patients even when disease duration is the same.
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: